Metabolomics and machine learning used to identify possible COVID-19 biomarkers

One of the many mysteries still surrounding COVID-19 is why some people experience only mild, flu-like symptoms, whereas others suffer life-threatening respiratory problems, vascular dysfunction and tissue damage.

Now, researchers reporting in ACS' Analytical Chemistry have used a combination of metabolomics and machine learning to identify possible biomarkers that could both help diagnose COVID-19 and assess the risk of developing severe illness.

Although some pre-existing conditions, such as diabetes or obesity, can increase the risk of hospitalization and death from COVID-19, some otherwise healthy people have also experienced severe symptoms. As most of the world's population awaits vaccination, the ability to simultaneously diagnose a patient and estimate their risk level could allow better medical decision-making, such as how closely to monitor a particular patient or where to allocate resources.

Therefore, Anderson Rocha, Rodrigo Ramos Catharino and colleagues wanted to use mass spectrometry combined with an artificial intelligence technique called machine learning to identify a panel of metabolites that could do just that.

The cross-sectional study included 442 patients who had different severities of COVID-19 symptoms and tested positive by a reverse transcriptase-polymerase chain reaction (RT-PCR) test, 350 controls who tested negative for COVID-19 and 23 people who were suspected of having the virus despite a negative RT-PCR test.

The researchers analyzed blood plasma samples from the participants with mass spectrometry and machine learning algorithms, identifying 19 potential biomarkers for COVID-19 diagnosis and 26 biomarkers that differed between mild and severe illnesses. Of the COVID-19-suspected patients, 78.3% tested positive with the new approach, possibly indicating these were RT-PCR false negatives.

Although the identified biomarkers, which included metabolites involved in viral recognition, inflammation, lipid remodeling and cholesterol homeostasis, need to be further verified, they could reveal new clues to how SARS-CoV-2 affects the body and causes severe illness, the researchers say.

Source:
Journal reference:

Delafiori, J., et al. (2021) Covid-19 Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning. Analytical Chemistry. doi.org/10.1021/acs.analchem.0c04497.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction